CRISPR Therapeutics AG Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
CRISPR Therapeutics AG quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q2 2024.
  • CRISPR Therapeutics AG Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $149M, a 6.79% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $149M -$10.8M -6.79% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $151M -$2.09M -1.36% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $154M -$2.93M -1.87% Dec 31, 2023 10-Q 2024-08-05
Q3 2023 $156M -$5.29M -3.28% Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $159M -$7.39M -4.43% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $153M -$18.2M -10.6% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $157M -$17.5M -10.1% Dec 31, 2022 10-K 2024-02-21
Q3 2022 $162M -$13.6M -7.78% Sep 30, 2022 10-Q 2022-11-01
Q2 2022 $167M -$12.6M -7.05% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $172M +$121M +242% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $174M +$124M +243% Dec 31, 2021 10-K 2023-02-21
Q3 2021 $175M +$137M +355% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $179M +$140M +356% Jun 30, 2021 10-Q 2021-07-29
Q1 2021 $50.1M +$9.81M +24.3% Mar 31, 2021 10-Q 2021-04-27
Q4 2020 $50.9M +$9.36M +22.6% Dec 31, 2020 10-K 2022-02-15
Q3 2020 $38.5M +$7.84M +25.6% Sep 30, 2020 10-Q 2020-10-28
Q2 2020 $39.3M +$8.53M +27.7% Jun 30, 2020 10-Q 2020-07-27
Q1 2020 $40.3M +$15.2M +60.7% Mar 31, 2020 10-Q 2020-04-28
Q4 2019 $41.5M Dec 31, 2019 10-K 2021-02-16
Q3 2019 $30.6M Sep 30, 2019 10-Q 2019-10-28
Q2 2019 $30.8M Jun 30, 2019 10-Q 2019-07-29
Q1 2019 $25.1M Mar 31, 2019 10-Q 2019-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.